In patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and ...

Researchers optimized healthcare AI for diagnoses, analyzed gender bias in image searches and found tiny DNA circles that ...

A new high-resolution neural recording method developed by Johns Hopkins APL and the School of Medicine detects neural ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated ...

--(BUSINESS WIRE)--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical ... those without the biomarker. Alto does not currently intend to advance ALTO-100 in MDD. ALTO-100 is currently being ...

Researchers successfully tested the safety and preliminary efficacy of stem-cell-derived corneal implants, showing promise ...

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and <a target=_blank href= ...

Background Licensing of tobacco retailers, including high retail licence fees, is one tobacco control measure that may reduce ...